Novavax Receives the Tech Council of Maryland’s Chairman’s Award
GAITHERSBURG, Md., 2016-05-12 14:30 CEST (GLOBE NEWSWIRE) --
Novavax, Inc., (Nasdaq:NVAX) a clinical-stage vaccine company focused on the discovery, development and commercialization of recombinant nanoparticle vaccines and adjuvants, today announced it received the Tech Council of Maryland’s (TCM) Chairman’s Award. The award was announced at the TCM Industry Award Celebration on May 11, 2016.
The Chairman's Award is presented to a member company or individual that best exemplifies excellence in Maryland's technology or life science industry. The Award recognizes a company that is a pillar in the community, not only through market success or job creation, but by consistently giving back, getting involved and advancing the climate for innovation.
“Novavax is the embodiment of what we look for when selecting an honoree for the Chairman’s award. The company has built a successful business, employing 450 people in Maryland who are developing vaccines that positively impact global health, and has played an important role in fostering growth of the state’s life sciences community,” said Rene B. LaVigne, TCM chairman-elect and president and CEO of Iron Bow Technologies. "TCM appreciates Novavax’s significant contributions to the association, the state’s economy and innovations in healthcare."
“I am honored to accept this award on behalf of the entire Novavax team,” said Stanley C. Erck, President and CEO, Novavax. “The Tech Council of Maryland facilitates a collaborative community of technology and life science companies who aim to make an impact in our region and beyond. We are thrilled that this award recognizes the hard work and dedication of our more than 450 SuperNovas, our groundbreaking achievements in developing novel vaccines and our commitment to the Maryland life science and technology community.”
Novavax, Inc. (Nasdaq:NVAX) is a clinical-stage vaccine company committed to delivering novel products to prevent a broad range of infectious diseases. Our recombinant nanoparticles and Matrix-M™ adjuvant technology are the foundation for groundbreaking innovation that improves global health through safe and effective vaccines. Additional information about Novavax is available on the Company's website,novavax.com.
Barclay A. Phillips
SVP, Chief Financial Officer and Treasurer
Andrea N. Flynn, Ph.D.
Associate Director, Investor Relations
Russo Partners, LLC
Todd Davenport, Ph.D.
Information om Globenewswire
Følg pressemeddelelser fra Globenewswire
Skriv dig op her og modtag pressemeddelelser på mail. Indtast din mail, klik på abonner og følg instruktionerne i den udsendte mail.
Flere pressemeddelelser fra Globenewswire
Meizu Technology ltd17.10.2018 15:15 | pressemeddelelse
Meizu officially launches its Overseas smartphone
Lithium Werks16.10.2018 14:39 | pressemeddelelse
€1.6bn investment project kickstarts Lithium Werks’ battery gigafactories vision
PureCircle16.10.2018 14:01 | pressemeddelelse
Global Beverage and Food Launches With Stevia Are Up Sharply In 2018
Talend16.10.2018 10:16 | pressemeddelelse
Talend Fall ’18 Enables Enterprises to Deliver Insight-Ready Data at Scale
Worksoft, Inc.16.10.2018 08:01 | pressemeddelelse
SAP® IT to Present on Agile Testing at SAP® TechEd® Barcelona Conference
LeddarTech inc.16.10.2018 07:01 | pressemeddelelse
LeddarTech Expands its Engineering Expertise and Accelerates its Design Roadmap to Meet Market Demand
I vores nyhedsrum kan du læse alle vores pressemeddelelser, tilgå materiale i form af billeder og dokumenter, og finde vores kontaktoplysninger.Besøg vores nyhedsrum